Searched for
SAMINA HAMIED CIPLA
Cipla shares in focus as promoters Samina and Rumana Hamied offload 1.72% stake for Rs 2,111 croreCipla shares are in focus today after Samina Hamied and Rumana Hamied, promoters of the pharmaceutical company, exited by selling their 1.7...- Promoters Samina and Rumana Hamied exit Cipla; sell 1.72 pc stake for Rs 2,111 croreSamina Hamied and Rumana Hamied, promoters of drug major Cipla, on Monday exited the pharmaceutical company by selling their 1.72 per cent ...
- Cipla's vice-chairman MK Hamied resigns citing age and health, his son Kamil to join the boardCipla's vice-chairman MK Hamied has resigned from the board due to age and health concerns, effective October 29, 2024. His son Kamil Hamie...
- Cipla promoters sell 2.53% stake for Rs 2,751 crore"Post transaction, the entire promoter group, including persons acting in concert, continues to hold 31.67% in the company and remains comm...
- Cipla promoters sell 2.53% stake for around Rs 2,600 crorePromoters of Cipla, including Person Acting in Concert, sold 2.04 crore shares in a block deal worth around Rs 2,600 crore to create liquid...
- Cipla promoters to sell up to 2.53% for Rs 2,637 croreThe move, days after the company posted its best annual results, has triggered speculation that more such transactions could be in the offi...
- Samina Hamied of Cipla steps down from her executive roleSamina Hamied, executive vice-chairperson of Cipla, announced her decision to step down from her executive role due to personal and family ...
- Samina Hamied to step down as Cipla executive vice chairpersonDrug major Cipla on Thursday said Samina Hamied has decided to step down from the position of Executive Vice Chairperson of the company, wh...
- Cipla founding family’s stake sale in jeopardy over $13 billion valuation targetProspective buyers of a stake in Indian pharmaceutical company Cipla Ltd. are hesitant due to the high valuation demanded by the founding f...
- Epic saga of Cipla: How a swadeshi Robin Hood took on Big Pharma of the WestCipla has been closely associated with India's struggle for independence, with Khwaja Abdul Hamied forming the company in 1935. For the Big...
- Cipla betting big on digitisation and emerging segmentsThe drug firm has embarked on the digital transformation of the value chain across functions, including finance, R&D, manufacturing, supply...
- ET Businesswoman of the Year 2021: Samina Hamied - The woman who carries forward a storied legacy, seeking profit, but never at the cost of values“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,00...
- Sell Cipla, target Rs 625: Jay ThakkarSell Cipla Ltd. at a price target of Rs 625 and a stop loss at Rs 651 from the entry point.
- Buy Cipla, target Rs 625: Dr CK NarayanBuy Cipla at a price target of Rs 625 and a stop loss at Rs 605 from entry point.
- Cipla names Samina Vaziralli as Executive Vice-ChairmanVaziralli, daughter of MK Hamied -- the company's non-executive VC - has been a part of the core leadership team since joining the Mumbai-b...
- YK Hamied to increase stake in Cipla to over 20 per centCipla patriarch YK Hamied plans to increase his holding to over 20 per cent by acquiring over 5 per cent additional stake in the homegrown ...
- Cipla inducts Samina Vaziralli, chairman YK Hamied's niece to company's boardSamina Vaziralli, niece of Cipla Chairman YK Hamied, was appointed to the company's board on Thursday, thus inducting the next generation.
- Cipla elevates Samina Vaziralli to its boardCipla today announced the appointment of Samina Vaziralli as executive director on its board, paving way for a bigger role for her.
- Successor-in-waiting Kamil Hamied leaves Cipla to pursue his own interestsKamil Hamied has quit Cipla, surprising those who had expected him to take a leadership role at India’s third-largest drug company.
- Cipla chief Yusuf K Hamied grooms niece & nephew Samina Vaziralli & Kamil Hamied as genext leadersEven as Hamied prepares genext leaders for Cipla, it’s humanitarian face is out to shake up industry by delivering affordable biosimilar dr...
Load More
